中文名稱: 兔抗LATS1/2(Phospho-Ser909/872)多克隆抗體
Background: |
LATS1 is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. Biochemical and genetic data suggest a role as a tumor suppressor. This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatments. LATS2 encodes a serine/threonine protein kinase belonging to the LATS tumor suppressor family. The protein localizes to centrosomes during interphase, and early and late metaphase. It interacts with the centrosomal proteins aurora-A and ajuba and is required for accumulation of gamma-tubulin and spindle formation at the onset of mitosis. It also interacts with a negative regulator of p53 and may function in a positive feedback loop with p53 that responds to cytoskeleton damage. Additionally, it can function as a co-repressor of androgen-responsive gene expression. |
Applications: |
WB |
Name of antibody: |
LATS1/2(Phospho-Ser909/872) |
Immunogen: |
Synthetic peptide of human LATS1/2 |
Full name: |
large tumor suppressor kinase 1/2 |
Synonyms: |
wts; WARTS; KPM |
SwissProt: |
O95835/Q9NRM7 |
WB Predicted band size: |
127/120 kDa |
WB Positive control: |
EGF treated HepG2 whole cell lysates |
WB Recommended dilution: |
500-1000 |